NDC 63323-286-01 - NAROPIN
This NDC is not currently matched to an FDA NDC product listing in FDA.report, but it is a valid NDC-form code. FDA.report is showing the available DailyMed label context for the product root.
- Product NDC
- 63323-286
- Requested NDC
- 63323-286-01
- Package NDCs from labels
- 63323-286-51, 63323-286-55, 63323-286-41, 63323-286-27, 63323-286-43, 63323-286-38, 63323-286-01, 63323-286-20, 63323-286-05, 63323-286-23, 63323-286-09, 63323-286-31, 63323-286-11, 63323-286-35, 63323-286-03, 63323-286-00, 63323-286-33, 63323-286-63, 63323-286-30, 63323-286-93, 63323-286-95
- Manufacturer
- Henry Schein, Inc.
- Effective date
- 2026-07-22
- Current FDA listing
- Not matched in FDA.report NDC product tables
DailyMed Labels#
| Label | Manufacturer | Effective date | Type |
|---|---|---|---|
| NAROPIN - Henry Schein, Inc. | Henry Schein, Inc. | 2026-07-22 | HUMAN PRESCRIPTION DRUG LABEL |
| Naropin - Fresenius Kabi USA, LLC | Fresenius Kabi USA, LLC | 2026-07-17 | HUMAN PRESCRIPTION DRUG LABEL |
| Naropin - Fresenius Kabi USA, LLC | Fresenius Kabi USA, LLC | 2024-08-15 | HUMAN PRESCRIPTION DRUG LABEL |
| Naropin - Fresenius Kabi USA, LLC | Fresenius Kabi Austria | HP Halden Pharma AS | Fresenius Kabi USA, LLC | Fresenius Kabi Austria | HP Halden Pharma AS | 2024-08-06 | HUMAN PRESCRIPTION DRUG LABEL |
| Naropin - Fresenius Kabi USA, LLC | Fresenius Kabi USA, LLC | 2024-07-10 | HUMAN PRESCRIPTION DRUG LABEL |
| NAROPIN - General Injectables & Vaccines, Inc | General Injectables & Vaccines, Inc | 2022-12-29 | HUMAN PRESCRIPTION DRUG LABEL |
| Naropin - APP Pharmaceuticals, LLC | Fresenius Kabi Norge AS | APP Pharmaceuticals, LLC | Fresenius Kabi Norge AS | 2011-09-15 | HUMAN PRESCRIPTION DRUG LABEL |
DailyMed Package Descriptions#
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 63323-286-00 | Naropin | 12 in 1 CASE | INJECTION, SOLUTION | 12 | 27 | |
| 63323-286-01 | Naropin | 20 mL in 1 AMPULE | INJECTION, SOLUTION | 20 | 27 | |
| 63323-286-03 | Naropin | 100 mL in 1 BOTTLE | INJECTION, SOLUTION | 100 | 27 | |
| 63323-286-05 | Naropin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 20 | 27 | |
| 63323-286-09 | Naropin | 30 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 30 | 27 | |
| 63323-286-11 | Naropin | 30 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 30 | 27 | |
| 63323-286-20 | Naropin | 5 in 1 BOX | INJECTION, SOLUTION | 5 | 27 | |
| 63323-286-23 | Naropin | 25 in 1 CARTON | INJECTION, SOLUTION | 25 | 27 | |
| 63323-286-30 | Naropin | 30 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 30 | 27 | |
| 63323-286-30 | Naropin | 1 in 1 BOX | INJECTION, SOLUTION | 1 | 27 | |
| 63323-286-31 | Naropin | 5 in 1 BOX | INJECTION, SOLUTION | 5 | 27 | |
| 63323-286-33 | Naropin | 200 mL in 1 BOTTLE | INJECTION, SOLUTION | 200 | 27 | |
| 63323-286-35 | Naropin | 25 in 1 CARTON | INJECTION, SOLUTION | 25 | 27 | |
| 63323-286-63 | Naropin | 12 in 1 CASE | INJECTION, SOLUTION | 12 | 27 | |
| 63323-286-93 | Naropin | 30 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 30 | 8 | |
| 63323-286-95 | Naropin | 25 in 1 TRAY | INJECTION, SOLUTION | 25 | 8 | |
| 63323-286-27 | Naropin | 25 in 1 CARTON | INJECTION, SOLUTION | 25 | 6 | |
| 63323-286-38 | Naropin | 25 in 1 CARTON | INJECTION, SOLUTION | 25 | 6 | |
| 63323-286-41 | Naropin | 20 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 20 | 6 | |
| 63323-286-43 | Naropin | 30 mL in 1 VIAL, SINGLE-DOSE | INJECTION, SOLUTION | 30 | 6 |
DailyMed Dashboard NDC Coverage#
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 63323-286 | NAROPIN (ROPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC ] | 27 | Current NDC, Legacy NDC, 14 package rows | 20240814_23d2d448-a744-4877-9f2d-7e57c198da89.zip |
| 63323-286 | NAROPIN (ROPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC ] | 8 | Current NDC, Legacy NDC, 2 package rows | 20240817_c6613708-c1f7-4f5c-91a3-ebbc1d7905c6.zip |
| 63323-286 | NAROPIN (ROPIVACAINE HYDROCHLORIDE) INJECTION, SOLUTION [FRESENIUS KABI USA, LLC ] | 6 | Current NDC, Legacy NDC, 4 package rows | 20240829_dff4a1e4-4b2a-4a64-b6d8-ea470dee88f7.zip |
DailyMed Billing Units#
DailyMed Socrata Ingredients#
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Adrenal Support | ADRENALINUM, BERBERIS VULGARIS, ARGENTUM NITRICUM, NATRUM MURIATICUM, VANADIUM METALLICUM, OLEUM MORRHUAE, PETROLEUM | NaturalCare | cee52757-a86e-4251-b65f-954ac85f4e7e | 2026-01-30 | Warnings | 451W47IQ8X |
| Vital Female Sexual Energy | AGNUS CASTUS, ARNICA MONTANA, AVENA SATIVA, CAULOPHYLLUM THALICTROIDES, CINCHONA OFFICINALIS, DAMIANA, HYPOPHYSIS SUIS, L-ARGININE, NATRUM MURIATICUM, OOPHORINUM SUIS, PHOSPHORICUM ACIDUM, SABAL SERRULATA, SEPIA, THUJA OCCIDENTALIS | Liddell Laboratories, Inc. | 7b15d6fa-eb04-41d2-8a01-6e7408ccf4d3 | 2026-01-30 | Warnings | 451W47IQ8X |
| Additive Formula 3 | DEXTROSE MONOHYDRATE, TRISODIUM CITRATE DIHYDRATE, SODIUM CHLORIDE, SODIUM PHOSPHATE, MONOBASIC, MONOHYDRATE, CITRIC ACID MONOHYDRATE, AND ADENINE | Terumo BCT, Ltd | 9a5247a1-cc05-442d-b2d0-950f887f03c2 | 2026-01-30 | Warnings, Adverse reactions | 451W47IQ8X |
| CVS ULTRA FINE MOISTURIZING SALINE MIST | NASAL MIST | CVS | 44821c47-63f9-5d0a-e063-6394a90a555d | 2026-01-29 | Warnings | 451W47IQ8X |
| Sodium Chloride | SODIUM CHLORIDE | Nephron Pharmaceuticals Corporation | a4edf2d5-a9ff-30d4-e053-2995a90a5650 | 2026-01-26 | Warnings, Adverse reactions | 451W47IQ8X |
| Ropivacaine Hydrochloride | ROPIVACAINE HYDROCHLORIDE | Hikma Pharmaceuticals USA Inc. | 3d465e02-fd09-41b8-847f-bfe99cb4a712 | 2026-01-21 | Warnings, Adverse reactions | 1734479 1734355 1734347 V910P86109 |
| Sodium Chloride | SODIUM CHLORIDE | ProPharma Distribution | 48d73434-e65b-dc98-e063-6294a90affa2 | 2026-01-20 | Adverse reactions | 451W47IQ8X |
| Equate Comfort Flow Sinus wash | SINUS WASH | WALMART INC | 9e911eef-ca99-9902-e053-2a95a90aab0e | 2026-01-19 | Warnings | 451W47IQ8X |
| EQUATE PREMIUM SALINE | SODIUM CHLORIDE 0.65% | Walmart Stores, Inc. | 1e17f022-f513-140d-e063-6394a90a379e | 2026-01-19 | Warnings | 451W47IQ8X |
| Sodium chloride | SODIUM CHLORIDE | Fresenius Kabi USA, LLC | d98bf9f7-30ec-4927-a577-cabad192cb18 | 2026-01-19 | Warnings, Adverse reactions | 451W47IQ8X |
| Sodium Chloride Hypertonicity | SODIUM CHLORIDE | CVS Pharmacy | 9245d842-7f78-42d8-83ba-8eb9ec8dbc0d | 2026-01-15 | Warnings | 451W47IQ8X |
| Sodium Chloride Hypertonicity | SODIUM CHLORIDE | CVS PHARMACY | d5cc6cd1-ddf8-4f5b-a021-204cdda0db94 | 2026-01-15 | Warnings | 451W47IQ8X |
| Constipation Relief | ALUMINUM OXIDE, BRYONIA ALBA ROOT, SODIUM CHLORIDE, GRAPHITE, SILICON DIOXIDE | Homeocare Laboratories | 62374240-cd14-44e2-9405-5f8996faf047 | 2026-01-12 | Warnings | 451W47IQ8X |
| Luffa | LUFFA, HYDRASTIS CANADENSIS, MERCURIUS SULPH. RUB, ALLIUM CEPA, NATRUM MURITICUM, PHOSPHORUS, EUPATORIUM PERF, STICTA | Marco Pharma International LLC. | 7dbb79de-c3f5-4245-884a-a6bd29bb861c | 2026-01-12 | Warnings | 451W47IQ8X |
| Hepaticol Drops 5008 | HEPATICOL DROPS | Professional Complementary Health Formulas | 79ee9e37-7853-4560-a87d-cdaefb603bbb | 2026-01-08 | Warnings | 451W47IQ8X |
| Weight Management Formula 7534 | WEIGHT MANAGEMENT FORMULA | Professional Complementary Health Formulas | f0406b63-7b97-4b2c-b976-75e8890818c6 | 2026-01-08 | Warnings | 451W47IQ8X |
| Acne Drops 2001 | ACNE DROPS | Professional Complementary Health Formulas | 340fc7dc-2aa4-411f-842b-4ce704671722 | 2026-01-08 | Warnings | 451W47IQ8X |
| Radialgin 6002 | RADIALGIN | Professional Complementary Health Formulas | 5e7ce7a0-9f43-4a69-89e9-a59692a8de41 | 2026-01-08 | Warnings | 451W47IQ8X |
| Viral Immune Stimulator 6017 | VIRAL IMMUNE STIMULATOR | Professional Complementary Health Formulas | f462cfb7-e1c3-4ded-9f79-f1983517fe15 | 2026-01-08 | Warnings | 451W47IQ8X |
| Pituitary Liquescence 3018 | PITUITARY LIQUESCENCE | Professional Complementary Health Formulas | a32e9ea9-5ff9-4951-9244-7b3253456b5f | 2026-01-08 | Warnings | 451W47IQ8X |
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.